MARKET WIREYahoo Finance • 1d ago
NEXGEL Announces 1-for-20 Reverse Stock Split EffectivenessYahoo Finance report covering NexGel Inc (NXGL) market action, institutional positioning, and fundamental catalysts.
Why NXGL Stock surged +18.21% Today — RQD Quant Desk Flash
$4.48 +18.21% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.62
NexGel Inc (NXGL) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $1.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on NXGL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is NXGL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, NexGel Inc (NASDAQ: NXGL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $4.48 (+18.21% 1D, market cap $1.8M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NXGL ranks #876 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does NXGL compare to IVF and BJDX in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), NXGL carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 39.5%, and ROIC of -35.0%. By comparison, IVF (INVO Fertility Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.1M) and BJDX (Bluejay Diagnostics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $2.4M). Among the 5-stock peer group, NXGL leads on earnings multiple (N/A) while NXGL leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for NXGL?
▼
Per NXGL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001468929), NexGel Inc generated $11.4M in revenue (+31.5% YoY), -$3.0M in net income, and -$1.4M in free cash flow against $10.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.62 (+3.09%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-13.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NXGL)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (28/100 Composite)
🔍 WHY NXGL SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9
▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (25% of score)
FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 43.3 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$5.46-3.3% Next Q
36
Q2 (-2Q)Grade E$5.28-23.7% Next Q
33
Q3 (-1Q)Grade E$4.03+11.2% Next Q
31
CurrentGrade E$4.48-10% Hist 90D α
28
Trajectory: E (36) → E (28)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a NXGL Turnaround Squeeze
While NXGL currently carries a cautious 28/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.94) and Max Pain ($4.70) forces dealer call-delta covering toward $56.28.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NXGL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NXGL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NXGL Stock surged +18.21% Today — RQD Quant Desk Flash
NexGel Inc (NXGL) surged +18.21% to $4.48, trading at 3% of its 52-week range ($3 – $53.6). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 3% of its 52-week range ($3 – $53.6) with RSI-14 at 43.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $4.48 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 39.5% gross margin and $0 annual free cash flow.
Live NXGL Headlines & Catalysts
MARKET WIRETradingView • 1d ago
NexGel, Inc Estimates – NASDAQ:NXGLTradingView report covering NexGel Inc (NXGL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREkalkine.ca • 2d ago
What Pushed NEXGEL (NASDAQ:NXGL) Down 19% Two Weeks After Its Share Consolidation?kalkine.ca report covering NexGel Inc (NXGL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 2d ago
NexGel Inc (NXGL) Edges Higher to $5.25 as Buyers Defend Key Support - Zero Gamma Levelhttps://www.siam.in/ report covering NexGel Inc (NXGL) market action, institutional positioning, and fundamental catalysts.
CATALYSTad-hoc-news.de • 2d ago
NEXGEL stock regains Nasdaq compliance after bid-price breachad-hoc-news.de report covering NexGel Inc (NXGL) market action, institutional positioning, and fundamental catalysts.
RISK WATCHhttps://www.dars.gov.et/ • 2d ago
NXGL Q2 2026 Earnings: Per-Share Loss of $7.40 Overshoots Estimates by 202% - Earnings Decline Riskhttps://www.dars.gov.et/ report covering NexGel Inc (NXGL) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 2d ago
Idexx Laboratories (IDXX) Beats Q3 Earnings and Revenue EstimatesIdexx (IDXX) delivered earnings and revenue surprises of +7.28% and +2.21%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
MARKET WIREYahoo • 7d ago
NEXGEL Regains Compliance with Nasdaq Listing RequirementLANGHORNE, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a company with a patient-centric medical technology sales and marketing team working closely with clinicians to p
MARKET WIREBenzinga • 8d ago
NEXGEL Regains Nasdaq ComplianceNEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL), a company with a patient-centric medical technology sales and marketing team working closely with clinicians to provide solutions that drive
MARKET WIREBenzinga • 8d ago
12 Health Care Stocks Moving In Monday's After-Market SessionGainers Senti Biosciences (NASDAQ:SNTI) stock rose 51.8% to $0.27 during Monday's after-market session. The company's market cap stands at $5.9 million. Polyrizon (NASDAQ:PLRZ) shares increased by 14.41% to
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NXGL)
- ✓Walkthrough of NXGL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NXGL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -62.10%▼ DESCENDING CHANNEL
2026-11-04O $3.51H $4.48L $3.51C $4.48VOL 18.3K
RES: $8.98SUP: $0.29SMA50: $4.94SMA200: $12.09
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NXGL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +31.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on NXGL today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NXGL. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NXGL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NXGL)
Health Care Rank #876 of 1015
⚔️ IVF vs NXGL Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NXGL vs. IVF, BJDX, VJET, ICCM)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, NexGel Inc (NXGL) ranks #876 by composite RQD confidence (28/100, grade E) and #996 by equity capitalization ($1.8M). Within this direct 5-issuer industry benchmark cohort, NXGL leads on earnings valuation at N/A trailing P/E, while NXGL leads on capital efficiency and profitability with -35.0% ROIC and 39.5% gross margin. BJDX currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with NXGL at 28/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NXGL
ACTIVE
NexGel Inc | E | 28/100 | — | 39.5% | -35.0% | +18.21% | $1.8M | Benchmark Subject |
| IVF INVO Fertility Inc. | D- | 35/100 | — | 96.0% | -35.0% | +6.01% | $2.1M | /ivf-vs-nxgl → |
| BJDX Bluejay Diagnostics Inc. | D- | 38/100 | — | — | -35.0% | +4.25% | $2.4M | /bjdx-vs-nxgl → |
| VJET Flyte Aviation Inc. | E | 30/100 | — | 92.3% | -35.0% | +0.02% | $1.2M | /vjet-vs-nxgl → |
| ICCM IceCure Medical Ltd. | E | 33/100 | — | 36.3% | -35.0% | -8.52% | $2.9M | /iccm-vs-nxgl → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001468929 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), NexGel Inc (NXGL) reported GAAP revenue of $11.4M (+31.5% vs. FY2024 revenue of $8.7M , and +179.3% cumulative change since FY2023) , GAAP net income of -$3.0M, operating cash flow of -$1.3M, and free cash flow of -$1.4M (+68.0% YoY). On the balance sheet, NXGL closed FY2025 with $10.5M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $11.4M | -$3.0M | -$1.3M | -$1.4M | $10.5M | — |
| FY2024 (FY) | 2024-12-31 | $8.7M | -$3.3M | -$3.9M | -$4.3M | $11.0M | — |
| FY2023 (FY) | 2023-12-31 | $4.1M | -$3.2M | -$3.2M | -$3.2M | — | — |
3. NXGL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NXGL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, NexGel Inc (NASDAQ: NXGL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $4.48 (+18.21% 1D, market cap $1.8M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NXGL ranks #876 in composite RQD confidence.
How does NXGL compare to IVF and BJDX in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), NXGL carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 39.5%, and ROIC of -35.0%. By comparison, IVF (INVO Fertility Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.1M) and BJDX (Bluejay Diagnostics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $2.4M). Among the 5-stock peer group, NXGL leads on earnings multiple (N/A) while NXGL leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NXGL?
Per NXGL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001468929), NexGel Inc generated $11.4M in revenue (+31.5% YoY), -$3.0M in net income, and -$1.4M in free cash flow against $10.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NXGL trading relative to its 50-day, 200-day, and 52-week technical levels?
NXGL last traded at $4.48 (+18.21% on volume of 22,175 shares), positioning the stock -9.31% below its 50-day simple moving average ($4.94) and -62.94% below its 200-day simple moving average ($12.09). Across its 52-week range of $3.00 to $53.60, NXGL sits at the 2.9% percentile with a 14-day RSI of 43.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.92 to $5.04).
ROARABLE RATING BRIEF • RQD 28/100 (E)
✓ SEC XBRL & RQD VERIFIED
NXGL — NexGel Inc: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
NexGel Inc (NXGL) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.48 (+18.21% 1D, market capitalization $1.8M).
- Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 39.5%, operating margin of -29.3%, and free cash flow yield of —.
- Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (7/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 5/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
NexGel Inc (NXGL) is a NASDAQ-listed Health Care issuer operating in the Medical/Dental Instruments industry. Products, customers, and revenue model details are — The source data reports FY 2025 revenue of $11.4M, indicating an operating business, though its composition is not described.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), NexGel Inc (NXGL) reported $11.4M in annual revenue (up from $8.7M in FY2024, +31.5% YoY) and -$3.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($4.1M revenue, -$3.2M net income) through FY2025, NXGL scaled operating cash flow to -$1.3M and free cash flow to -$1.4M, backed by $10.5M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 28/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $3.00 – $53.60 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -29.3% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies are — Sector correlations beyond the Health Care sector classification are — Second-order bottlenecks cannot be identified from the provided data.
- Key Question #1: Can NXGL sustain or expand its -29.3% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $11.4M and free cash flow of -$1.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is NXGL's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
NXGL Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for NexGel Inc (NXGL) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 1d ago
NEXGEL Announces 1-for-20 Reverse Stock Split Effectiveness Yahoo Finance report covering NexGel Inc (NXGL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
NexGel, Inc Estimates – NASDAQ:NXGL TradingView report covering NexGel Inc (NXGL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE kalkine.ca • 2d ago
What Pushed NEXGEL (NASDAQ:NXGL) Down 19% Two Weeks After Its Share Consolidation? kalkine.ca report covering NexGel Inc (NXGL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 2d ago
NexGel Inc (NXGL) Edges Higher to $5.25 as Buyers Defend Key Support - Zero Gamma Level https://www.siam.in/ report covering NexGel Inc (NXGL) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST ad-hoc-news.de • 2d ago
NEXGEL stock regains Nasdaq compliance after bid-price breach ad-hoc-news.de report covering NexGel Inc (NXGL) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH https://www.dars.gov.et/ • 2d ago
NXGL Q2 2026 Earnings: Per-Share Loss of $7.40 Overshoots Estimates by 202% - Earnings Decline Risk https://www.dars.gov.et/ report covering NexGel Inc (NXGL) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo • 2d ago
Idexx Laboratories (IDXX) Beats Q3 Earnings and Revenue Estimates Idexx (IDXX) delivered earnings and revenue surprises of +7.28% and +2.21%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
🟡 MARKET WIRE Yahoo • 7d ago
NEXGEL Regains Compliance with Nasdaq Listing Requirement LANGHORNE, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a company with a patient-centric medical technology sales and marketing team working closely with clinicians to p
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
NXGL Bull vs. Bear Conversation Board — What's Your Call at $4.48?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NXGL 🐻 33% BEARISH CONVICTION
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH
🎯 Target: $4.07 (+16.0%)
📌 Pinned Debate Revenue more than doubled from $4.1M in FY 2023 to $11.4M in FY 2025 while the stock regained Nasdaq compliance.
Picked up a starter position in NXGL in my $100K Virtual Cash book at $3.51. Revenue more than doubled from $4.1M in FY 2023 to $11.4M in FY 2025 while the stock regained Nasdaq compliance.. Trading inside a $3.00–$53.60 52-week range with 0.0% FCF yield gives solid downside support if Medical/Dental Instruments multiples expand this quarter.
CapAlloc_Nerd 🐂 BULL
@FadeTheHype Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (39.5%) holds, EPS grows into the multiple faster than bears think.
FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH
🎯 Target: $2.74 (-21.9%)
Spot @ $3.51 A -35% ROIC, 0.2 Altman Z-Score, and 0% FCF yield indicate weak returns and elevated distress risk.
Here is the bear case nobody on the bull side wants to address on NXGL: A -35% ROIC, 0.2 Altman Z-Score, and 0% FCF yield indicate weak returns and elevated distress risk.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.